Gland Pharma Ltd. · NSE:GLAND

Gland Pharma — Q1 FY23 Earnings Presentation

11 slides from Gland Pharma's earnings presentation, Jul 20, 2022

  1. Slide 1: Gland Pharma Limited Financial Results Q1 FY23

    Gland Pharma Limited Financial Results Q1’FY23 20th July 2022

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation

  3. Slide 3: Financial Highlights (1/3)

    Financial Highlights (1/3) Maintain profitability despite supply chain disruption Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn) (INR Mn / %) 11,030 4,136 4,981 3,443 11,539 8,569 8,569 3,443 37% 35% 41% 37% Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 Q1 FY22 Q1 FY23 Q4 FY22 Q1 FY23 PBT / PAT /

  4. Slide 4: Financial Highlights (2/3)

    Financial Highlights (2/3) Strong Balance Sheet to support future growth plans Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) 74,061 (INR Mn) 71,576 12,250 37,892 37,853 12,250 34,483 34,444 59,326 61,811 Mar'22 Jun'22 Mar'22 Jun'22 Networth Fresh issue of equity Total Cash Net Cash Ne

  5. Slide 5: Financial Highlights (3/3)

    Financial Highlights (3/3) Focus on capital efficiency and ramping-up new capacities Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 3.6 42% 2.8 33% 2.2 23% 21% 18% 12% 0.7 0.7 23% 19% 0.5 13% Total asset turnover Fixed asset turnover Q1 FY22 FY22 Q1 FY23 Q1 FY22 FY22 Q1 FY23

  6. Slide 6: P&L Highlights

    P&L Highlights (INR Mn) YoY QoQ Particulars Q1 FY23 Q1 FY22 Q1 FY23 Q4 FY22 FY22 change change Revenue from operations 8,569 11,539 -26% 8,569 11,030 -22% 44,007 Other Income (excluding Forex gain) 402 341 18% 402 380 6% 1,447 Forex gain (net) 342 277 24% 342 272 26% 792 Total Income 9,313 12,157 -2

  7. Slide 7: USA, Europe, Canada and Australia (Core Markets)

    USA, Europe, Canada and Australia (Core Markets)  Revenue: Q1 FY23: Rs. 7,056 Mn YoY Change: -6% Ensured timely new product launches and commercialized key products such as Bortezomib, Pemetrexed, Pantoprazole and Cyanocobalamin in the US market. Core Markets (1) Received 180 days CGT exclusivity f

  8. Slide 8: Rest of the World Markets

    Rest of the World Markets  Delay in material supplies impacted our ability to take Q1 FY23: Rs. 1,002 Mn YoY Change: -55% up orders with low delivery times.  Demand remains strong and we are working to build Rest of the World Markets inventory to meet the growing demand.  Our key markets contribu

  9. Slide 9: India (Domestic Market)

    India (Domestic Market)  India market sales accounted for 6% of our total sales Q1 FY23: Rs. 510 Mn YoY Change: -72% during Q1 FY23.  Shutdown of dedicated insulin line taken for increasing India (Domestic Market) the line productivity impacted quarterly sales. Shortfall in Insulin production to b

  10. Slide 10: Growth Drivers

    Growth Drivers 1  China remains a key geographic focus and we expect to start receiving approvals for at least a couple of Geographic products during the current year as the inspection has been waived off Expansion  We have also finalized next set of product filings for China with an addressable m

  11. Slide 11: GLAND

    Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder

Gland Pharma — Q1 FY23 Earnings Presentation on 6ix